Universal Biosensors refuses to deny acquisition rumours
Monday, 13 September, 2010
Responding to reports in ALS last Friday that his company may be on the market, Univeral Biosensors chairman and interim CEO Andy Denver said today that “we are always up for sale”.
Universal Biosensors announced last week that its CEO Mark Morrission was retiring, leading to speculation that he was making way for a major structural change.
A number of possible suitors have been mooted, most notably Johnson & Johnson, which already owns 12 percent of Universal Biosensors. The two companies also have a joint product development agreement in Australia.
J&J declined last Friday to comment on the rumours.
Existing shareholders CM Capital and Principals Cornerstone Fund, would also stand to gain from an acquisition of Universal Biosensors.
Denver refused, however, to be drawn on whether Universal Biosensors was about to announce a deal with J&J or any other company. Shares in Universal Biosensors rose a cent to close at $1.52 today.
Reproductive impacts of PFAS exposure revealed
New studies have found that PFAS exposure can significantly alter male reproductive health, and...
'Longevity gene' could reverse damage from rapid aging disease
A gene found in supercentenarians, who live exceptionally long lives, could counteract the...
How a common gene mutation increases liver disease risk
Liver damage can be caused in people after exposure to high levels of acrolein, especially in...
